TJ011133

DRUG2 trials

Sponsors

I-Mab Biopharma US Limited, TJ Biopharma Co., Ltd.

Conditions

Acute Myeloid Leukemia (AML)LymphomaMyelodysplastic Syndromes(MDS)Solid Tumor

Phase 1

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

CompletedNCT03934814

I-Mab Biopharma US LimitedLymphoma, Solid Tumor

Start: 2019-04-16End: 2023-01-10Updated: 2024-07-01

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CompletedNCT04202003

TJ Biopharma Co., Ltd.Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS)

Start: 2020-03-25End: 2023-12-15Updated: 2024-04-15

Related Papers

Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results

Blood2021-11-0531 citations

A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results

Blood2020-11-0438 citations

385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results

Regular and Young Investigator Award Abstracts2020-11-0115 citations